Does Rallies show Form 4 insider transactions for ACLX?

Yes. Rallies tracks ACLX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ACLX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ACLX. It does not provide personalized investment advice.

ACLX (Arcellx, Inc. Common Stock) Stock Analysis - Insider Trades

Arcellx, Inc. Common Stock (ACLX) is a publicly traded Healthcare sector company. As of May 21, 2026, ACLX trades at $115.07 with a market cap of $6.73B and a P/E ratio of -28.27. ACLX moved +0.03% today. Year to date, ACLX is +62.44%; over the trailing twelve months it is +80.62%. Its 52-week range spans $47.86 to $115.13. Analyst consensus is hold with an average price target of $112.45. Rallies surfaces ACLX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ACLX stock inside the company?

Recent ACLX insider activity includes Elghandour Rami sold 89.92K, Gilson Michelle sold 11.22K, Gilson Michelle sold 2.88K, Gilson Michelle sold 5.41K, and Gilson Michelle sold 100. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ACLX Key Metrics

Key financial metrics for ACLX
Metric	Value
Price	$115.07
Market Cap	$6.73B
P/E Ratio	-28.27
EPS	$-4.07
Dividend Yield	0.00%
52-Week High	$115.13
52-Week Low	$47.86
Volume	16.12M
Avg Volume	0
Revenue (TTM)	$22.29M
Net Income	$-228.93M
Gross Margin	0.00%

Recent ACLX Insider Trades

Elghandour Rami sold 89.92K (~$10.24M) on Feb 27, 2026.
Gilson Michelle sold 11.22K (~$1.28M) on Feb 25, 2026.
Gilson Michelle sold 2.88K (~$194.99K) on Feb 19, 2026.
Gilson Michelle sold 5.41K (~$370.63K) on Feb 19, 2026.
Gilson Michelle sold 100 (~$6.94K) on Feb 19, 2026.

Latest ACLX News

Gilead’s $7.8B Arcellx Purchase Is Third Oncology Acquisition — Apr 7, 2026
Gilead to Acquire Arcellx for $7.8B, Securing CAR-T Therapy Rights — Mar 25, 2026
Gilead to acquire Arcellx for $115 per share plus $5 CVR, valuing at $7.8B — Mar 23, 2026
Arcellx Shareholder Suit Targets $115 Cash and $5 CVR Gilead Deal — Mar 19, 2026
Arcellx CFO Sells 11,219 Shares at $113.82 as P/E Dives to -29.5 — Feb 26, 2026

ACLX Analyst Consensus

18 analysts cover ACLX: 0 strong buy, 7 buy, 11 hold, 0 sell, 0 strong sell. Consensus rating is hold. Average price target: $112.45.

Common questions about ACLX

Who is trading ACLX stock inside the company?: Recent ACLX insider activity includes Elghandour Rami sold 89.92K, Gilson Michelle sold 11.22K, Gilson Michelle sold 2.88K, Gilson Michelle sold 5.41K, and Gilson Michelle sold 100. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ACLX?: Yes. Rallies tracks ACLX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ACLX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ACLX. It does not provide personalized investment advice.